U3 1784

Drug Profile

U3 1784

Alternative Names: U3-1784

Latest Information Update: 19 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator U3 Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Type 4 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Liver cancer; Solid tumours

Most Recent Events

  • 01 May 2017 Discontinued - Phase-I for Liver cancer (Late-stage disease, Second-line therapy or greater) in United Kingdom (IV) (Daiichi Sankyo pipeline, May 2017)
  • 01 May 2017 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in United Kingdom (IV) (Daiichi Sankyo pipeline, May 2017)
  • 16 Apr 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top